SOCS2 and breast cancer: In 2020, the same group focused on another CAF-released miRNA, miR-3613-3p, demonstrating its role as oncogene, promoting breast cancer drug resistance, ROS production and metastasis through the inhibition of suppressor of cytokine signaling 2 (SOCS2) [51].